Opinion: Bad Sport Management Decisions: Tim Tebow & Matt Harvey

  • by: Alan Duke

By Brian Bielanski, Lead Stories Contributor

I woke up this morning to two stories I just can't figure out. The first is the decision by the Philadelphia Eagles to cut Tim Tebow and then sign a guy that has never started a game in the NFL and wasn't good enough to make the Jacksonville Jaguars practice squad. The second is the decision to shut down New York Mets' pitcher Matt Harvey because he has pitched too many innings after having Tommy John surgery.

Why in the world would the Eagles cut a guy who performed pretty well throughout the pre-season just to bring in a guy off another team's practice squad who's never seen the playbook or played a down in your system? I'm not a Tebow fan or a Tebow hater. He seems like a good guy and good role model potential, but more importantly he's worked his tail off and shown a huge amount of improvement. He's also started and won games in the NFL. He has to be better prepared than Stephen Morris. Lord knows (see what I did there) they'll sell a bunch of Tebow jerseys.

Then in New York, you have a pitcher who is on a 180 inning limit because he's coming off Tommy John Surgery. I get that, but what I don't get is how once again the team, the player, his doctors and agent have so completely botched the management of the inning limit. Why not have him skip a start every month so you have him available for the stretch run and the playoffs?

I don't get the idea of getting to September 1st and having to shut a guy down when the team is in the playoff hunt. Bring up a prospect in April and May and pitch the guy every third start. It gives the prospect some experience in the big show and gets your veteran to September where he's useful. I can't imagine pitching on a chilly night in Queens in April is good for a guy coming off Tommy John surgery. Skipping starts early makes much more sense than skipping starts late.

This isn't the first time it has happened. The Washington Nationals had the same issue in 2012 with Stephen Strasburg. You would have thought the Mets would have learned something from that. Or maybe the Mets figured they wouldn't be in contention in September so they never anticipated a problem.

Thumbnail image for Thumbnail image for Brian Bielanksi headshot.png

Brian Bielanski has covered the NFL, NBA, MLB, college football, basketball and baseball, the Final Four, the PGA Tour and motorsports over the past 23 years as a radio talk show host and play-by-play announcer, and as a TV news producer for CNN and CBS.

Lead Stories' Tendolizer is a big sports fan and scours social nets 24-7 for the hottest trending content about pro baseball and football. Scroll down to see the latest.


  Alan Duke

Editor-in-Chief Alan Duke co-founded Lead Stories after ending a 26-year career with CNN, where he mainly covered entertainment, current affairs and politics. Duke closely covered domestic terrorism cases for CNN, including the Oklahoma City federal building bombing, the UNABOMBER and search for Southeast bomber Eric Robert Rudolph. CNN moved Duke to Los Angeles in 2009 to cover the entertainment beat. Duke also co-hosted a daily podcast with former HLN host Nancy Grace, "Crime Stories with Nancy Grace" and hosted the podcast series "Stan Lee's World: His Real Life Battle with Heroes & Villains." You'll also see Duke in many news documentaries, including on the Reelz channel, CNN and HLN.

Read more about or contact Alan Duke

About Us

International Fact-Checking Organization Meta Third-Party Fact Checker

Lead Stories is a fact checking website that is always looking for the latest false, misleading, deceptive or inaccurate stories, videos or images going viral on the internet.
Spotted something? Let us know!.

Lead Stories is a:


@leadstories

Subscribe to our newsletter

* indicates required

Please select all the ways you would like to hear from Lead Stories LLC:

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Most Read

Most Recent

Share your opinion